Evidence map›Paper›PMID 32985540›Full record

ArticleScientific reports2020

Development of fully automated and ultrasensitive assays for urinary adiponectin and their application as novel biomarkers for diabetic kidney disease.

Toshihiro Watanabe, Yuki Fujimoto, Aya Morimoto, Mai Nishiyama, Akinori Kawai, Seiki Okada, Motohiro Aiba, Tomoharu Kawano, Mina Kawahigashi, Masashi Ishizu and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Yishen Capsule Alleviated Symptoms of Diabetic Nephropathy via NOD-like Receptor Signaling Pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Toshihiro WatanabeR&D Division, Sysmex R&D Center Americas, Inc., Mundelein, IL, USA. Watanabe.Toshihiro@sysmex.co.jp.
Yuki FujimotoLife Style Diseases, Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan.
Aya MorimotoClinical Innovation, Sysmex Corporation, Kobe, Hyogo, Japan.
Mai NishiyamaClinical Innovation, Sysmex Corporation, Kobe, Hyogo, Japan.
Akinori KawaiClinical Innovation, Sysmex Corporation, Kobe, Hyogo, Japan.
Seiki OkadaClinical Innovation, Sysmex Corporation, Kobe, Hyogo, Japan.
Motohiro AibaLife Style Diseases, Institute for Health Sciences, Tokushima Bunri University, Tokushima, Japan.
Tomoharu KawanoHuman Life Science, Tokushima Bunri University, Tokushima, Japan.
Mina KawahigashiHuman Life Science, Tokushima Bunri University, Tokushima, Japan.
Masashi IshizuDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Hiroyasu MoriDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Munehide MatsuhisaDiabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
Akiko HataClinical Research Center for Diabetes, Tokushima University Hospital, Tokushima, Japan.
Makoto FunakiClinical Research Center for Diabetes, Tokushima University Hospital, Tokushima, Japan.
Seiichi HashidaDepartment of Diabetes and Molecular Genetics, Ehime University Graduate School of Medicine, Ehime, Japan.
Sysmex (Japan) · JPTokushima Bunri University · JPTokushima University · JPTokushima University Hospital · JPEhime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glomerular filtration rate (GFR) and urinary albumin excretion rate (UAER) are used to diagnose and classify the severity of chronic kidney disease. Total adiponectin (T-AN) and high molecular weight adiponectin (H-AN) assays were developed using the fully automated immunoassay system, HI-1000 and their significance over conventional biomarkers were investigated. The T-AN and H-AN assays had high reproducibility, good linearity, and sufficient sensitivity to detect trace amounts of adiponectin in the urine. Urine samples after gel filtration were analyzed for the presence of different molecular isoforms. Low molecular weight (LMW) forms and monomers were the major components (93%) of adiponectin in the urine from a diabetic patient with normoalbuminuria. Urine from a microalbuminuria patient contained both high molecular weight (HMW) (11%) and middle molecular weight (MMW) (28%) adiponectin, although the LMW level was still high (52%). The amount of HMW (32%) and MMW (42%) were more abundant than that of LMW (24%) in a diabetic patient with macroalbuminuria. T-AN (r = - 0.43) and H-AN (r = - 0.38) levels showed higher correlation with estimated GFR (eGFR) than UAER (r = - 0.23). Urinary levels of both T-AN and H-AN negatively correlated with renal function in diabetic patients and they may serve as new biomarkers for diabetic kidney disease.

Indexed as

Limit of DetectionAdiponectinAdultAgedAutomationBiomarkersDiabetic NephropathiesFemaleHumansMaleMiddle AgedMolecular WeightProtein MultimerizationProtein Structure, QuaternaryUrinalysisAdiponectinBiomarkers

Identifiers

PMID32985540
PMCPMC7522970
OpenAlexW3088373878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.